AnaptysBio, Inc. (NASDAQ:ANAB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.
According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
A number of other research analysts also recently weighed in on ANAB. Credit Suisse Group upped their target price on AnaptysBio from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, August 25th. Stifel Nicolaus reiterated a “buy” rating and set a $35.00 target price on shares of AnaptysBio in a report on Tuesday, September 12th. Royal Bank Of Canada initiated coverage on AnaptysBio in a report on Thursday, September 14th. They set an “outperform” rating and a $40.00 target price on the stock. JMP Securities upped their target price on AnaptysBio from $45.00 to $82.00 and gave the stock an “outperform” rating in a report on Tuesday, October 10th. Finally, Robert W. Baird set a $69.00 target price on AnaptysBio and gave the stock a “buy” rating in a report on Wednesday, October 11th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $76.25.
Shares of AnaptysBio (NASDAQ ANAB) traded down $0.60 during trading hours on Friday, reaching $66.50. The company had a trading volume of 199,900 shares, compared to its average volume of 425,939. AnaptysBio has a 52 week low of $15.17 and a 52 week high of $74.00. The company has a current ratio of 10.77, a quick ratio of 11.50 and a debt-to-equity ratio of 0.09.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02. analysts expect that AnaptysBio will post -1.72 earnings per share for the current fiscal year.
In related news, major shareholder Holdings A/S Novo sold 356,300 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $21.10, for a total value of $7,517,930.00. Following the transaction, the insider now directly owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its position in AnaptysBio by 160.8% in the 3rd quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 1,951 shares in the last quarter. Bank of America Corp DE bought a new position in AnaptysBio in the 1st quarter valued at approximately $123,000. DAFNA Capital Management LLC lifted its position in AnaptysBio by 22.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 1,000 shares in the last quarter. New York State Common Retirement Fund bought a new position in AnaptysBio in the 2nd quarter valued at approximately $168,000. Finally, Nationwide Fund Advisors lifted its position in AnaptysBio by 89.5% in the 3rd quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 2,776 shares in the last quarter. 59.40% of the stock is currently owned by institutional investors and hedge funds.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.